{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "AIFF",
  "name": "Firefly Neuroscience, Inc.",
  "url": "https://frontierpicks.com/dossiers/AIFF/",
  "json_url": "https://frontierpicks.com/dossiers/AIFF.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a7",
    "n": 7
  },
  "current_thesis": "Firefly Neuroscience's September partnership rally has reversed and the shares closed at $0.92 on 23 October 2026, under Nasdaq's $1.00 minimum; the third-quarter report around 12 November 2026 shows whether revenue beats $514,000.",
  "invalidation_trigger": "A daily close below $0.80, which would extend the reversal below the current lows. A third-quarter report showing revenue at or below the $514,000 second-quarter level would also break the case.",
  "catalyst_date": "2026-11-12",
  "pick": null,
  "themes": [
    "medtech-diagnostics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "The June 2026 Form 10-Q includes a going-concern warning: management states substantial doubt about continuing operations for one year.",
    "The $7.43 million at-the-market equity program opened on 2026-02-03 lets the company sell new shares into the market without a separate offering announcement.",
    "Nasdaq's minimum bid price rule requires a $1.00 close; a deficiency notice follows 30 consecutive business days below it."
  ],
  "source_links": [],
  "body_markdown": "## Current Thesis\nFirefly Neuroscience's September partnership rally has fully reversed, and the shares now trade below the Nasdaq $1.00 minimum bid price. The third-quarter report, expected around 2026-11-12, settles whether the Radial and NeuroSigma deals add revenue to the $514,000 reported for the second quarter.\n\nThe narrative is dead in price terms: the shares closed at $0.92 on 2026-10-23, well under the $1.58 intraday price Benzinga reported on 2026-09-25, the day the NeuroSigma partnership was announced. The prior note's $1.00 failure line has been breached. The shares closed at $1.19 on 2026-10-09 and at $0.92 two weeks later, according to adjusted daily closes. No company news after the 2026-10-01 investor-conference appearance has appeared in company releases or news searches.\n\n## Bull Case\n- **Revenue is growing from a small base.** The June 2026 Form 10-Q reports second-quarter revenue of $514,000, against $299,000 a year earlier.\n- **Losses have narrowed sharply.** The same 10-Q reports a six-month net loss of $3.99 million through 2026-06-30, against $14.76 million a year earlier.\n- **Two new distribution channels exist.** On 2026-09-17 Firefly announced work to integrate its Evoke EEG/ERP brain-measurement platform with Radial's RadialOS. On 2026-09-25 NeuroSigma assigned Firefly clinician introductions and education for its FDA-cleared Monarch eTNS pediatric attention-deficit/hyperactivity disorder (ADHD) device.\n- **The shares are deeply oversold.** The 14-day relative strength index (RSI) was 16.1 on 2026-10-23, a reading that has historically preceded rebounds in some cases and further declines in others.\n\n## Bear Case\n- **The deals carry no stated economics.** Neither the 2026-09-17 Radial release nor the 2026-09-25 NeuroSigma release puts a number on revenue to Firefly.\n- **Going-concern doubt is unresolved.** The June 2026 Form 10-Q states substantial doubt about continuing operations for one year. It reported cash of $9.23 million at 2026-06-30, against $3.70 million used in operations in the first half.\n- **Share supply is available.** The $7.43 million at-the-market equity program opened on 2026-02-03 had no sales through 2026-06-30. A lower share price means any sales would issue more shares per dollar raised. The 10-Q cover showed 15,690,316 shares outstanding on 2026-08-04.\n- **The listing is under pressure.** The 2026-10-23 close of $0.92 is below Nasdaq's $1.00 minimum bid price. A deficiency notice follows 30 consecutive business days below that level. The start date of the sub-$1.00 run is not established in the sources reviewed.\n- **Finance leadership is in transition.** An 8-K filed 2026-09-14 disclosed the termination of chief financial officer Paul Krzywicki, effective 2026-09-24, and the appointment of a chief accounting officer.\n\n## Setup & Price Structure\nThe shares closed at $0.92 on 2026-10-23 on split- and dividend-adjusted daily bars. That is 69.5% below the 52-week high of $3.02 and 16.8% lower over three months. The RSI of 16.1 shows selling that is extreme by its own history.\n\nCrowding is absent. Benzinga's health-care movers lists picked up the 33.2% jump to $1.58 on 2026-09-25, and that attention has faded. Form 4 filings dated 2026-09-29 showed directors receiving deferred stock unit grants, not open-market sales. The unused at-the-market program is the visible source of potential new supply. The third-quarter report is the one near-term event.\n\n## Catalyst Calendar (next 30 days)\n- **~2026-11-12, est.: Third-quarter 2026 results and Form 10-Q.** One financial calendar lists this date; the company has not confirmed it in the sources reviewed. The filing shows revenue against $514,000, any at-the-market sales, cash remaining and the going-concern language.\n- **Any date: Nasdaq deficiency notice.** An 8-K would follow 30 consecutive business days of closes below $1.00.\n\n## What Would Change Our Mind\nThe case breaks if third-quarter revenue is at or below the $514,000 second-quarter level with no revenue attributed to Radial or NeuroSigma. It also breaks if the 10-Q shows at-the-market sales that fund losses at the current price, or if the company announces a discounted registered offering. A third-quarter figure clearly above $514,000 with attributed partner revenue would strengthen it. Price-wise, a daily close below $0.80 would extend the reversal beyond the current lows.\n\n## Correlation Notes\nFirefly trades on its own news flow and financing events, not on a sector. The 2026-09-25 move appeared in Benzinga's lists of small health-care stocks that jump on single announcements, and the shares have since given the move back. The shares are not part of a current theme cluster. The sample of post-announcement trading days is too small to say how the shares react to the report.",
  "first_seen": "2026-09-27",
  "last_analyzed": "2026-10-25T12:04:24+00:00",
  "last_synthesized": "2026-10-25",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}